双输入灌注CT预测非小细胞肺癌化疗疗效:贝伐珠单抗治疗、不含贝伐珠单抗的两药铂类治疗及其他非贝伐珠单抗治疗组的比较
本研究纳入66例III或IV期非小细胞肺癌化疗患者,分为贝伐珠单抗组(20例)、不含贝伐珠单抗的两药铂类组(25例)和其他非贝伐珠单抗组(21例),治疗前用双输入灌注CT计算肺动脉灌注和支气管动脉灌注。贝伐珠单抗组治疗前支气管动脉灌注与两周期化疗后肿瘤缩小率独立相关(P=0.006),且与死亡累积风险(P=0.006)和化疗后疾病进展(P=0.015)显著相关。治疗前肺动脉灌注和临床参数在三组中均不是疗效或预后的显著预测因素。
要点
- 贝伐珠单抗组治疗前支气管动脉灌注与两周期化疗后肿瘤缩小率独立相关(P=0.006)。
- 贝伐珠单抗组治疗前支气管动脉灌注与死亡累积风险(P=0.006)和疾病进展(P=0.015)显著相关。
- 治疗前肺动脉灌注和临床参数在三组中均非疗效或预后的显著预测因素。
核心结论
- 双输入灌注CT得出的治疗前支气管动脉灌注似乎是有望帮助预测非小细胞肺癌患者贝伐珠单抗化疗疗效的工具。
研究设计与样本
- 经机构审查委员会批准并获知情同意的研究,纳入66例接受化疗的III或IV期非小细胞肺癌患者(42男,24女,平均年龄63.4岁),分为贝伐珠单抗组(n=20)、不含贝伐珠单抗的两药铂类组(n=25)和其他非贝伐珠单抗治疗组(n=21),治疗前用双输入灌注CT计算肿瘤的肺动脉灌注和支气管动脉灌注,采用单变量和多变量分析(肿瘤缩小率用多元线性回归,预后用Cox比例风险模型)识别两周期化疗后肿瘤缩小和预后的预测因素。
诊断标准与关键数值
- 贝伐珠单抗组治疗前支气管动脉灌注与两周期化疗后肿瘤缩小率独立相关(P=0.006)。
- 贝伐珠单抗组治疗前支气管动脉灌注与死亡累积风险显著相关(P=0.006)。
- 贝伐珠单抗组治疗前支气管动脉灌注与化疗后疾病进展显著相关(P=0.015)。
- 治疗前肺动脉灌注和临床参数在三组中均不是疗效或预后的显著预测因素。
临床应用与阅片要点
- 作者认为,双输入灌注CT得出的治疗前支气管动脉灌注似乎是有望帮助预测非小细胞肺癌患者贝伐珠单抗化疗疗效的工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To determine whether dual-input perfusion computed tomography (CT) can predict therapeutic response and prognosis in patients who underwent chemotherapy for non-small cell lung cancer (NSCLC). Materials and Methods The institutional review board approved this study and informed consent was obtained. Sixty-six patients with stage III or IV NSCLC (42 men, 24 women; mean age, 63.4 years) who underwent chemotherapy were enrolled. Patients were separated into three groups: those who received chemotherapy with bevacizumab (BV) (n = 20), those who received two-agent platinum-based therapy without BV (n = 25), and those who received other non-BV treatment (n = 21). Before treatment, pulmonary artery perfusion (PAP) and bronchial artery perfusion (BAP) of the tumors were calculated. Predictors of tumor reduction after two courses of chemotherapy and prognosis were identified by using univariate and multivariate analyses. Covariates included were age, sex, patient's performance status, baseline maximum diameter of the tumor, clinical stage, pretreatment PAP, and pretreatment BAP. For multivariate analyses, multiple linear regression analysis for tumor reduction rate and Cox proportional hazards model for prognosis were performed, respectively. Results Pretreatment BAP was independently correlated with tumor reduction rate after two courses of chemotherapy in the BV treatment group (P = .006). Pretreatment BAP was significantly associated with a highly cumulative risk of death (P = .006) and disease progression after chemotherapy (P = .015) in the BV treatment group. Pretreatment PAP and clinical parameters were not significant predictors of therapeutic effect or prognosis in three treatment groups. Conclusion Pretreatment BAP derived from dual-input perfusion CT seems to be a promising tool to help predict responses to chemotherapy with BV in patients with NSCLC. © RSNA, 2017.
引用
- Yabuuchi H, Kawanami S, Iwama E, et al. Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups. Radiology. 2017. PMID: 29059037. doi:10.1148/radiol.2017162204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。